BR112021024001A2 - Formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesma - Google Patents
Formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesmaInfo
- Publication number
- BR112021024001A2 BR112021024001A2 BR112021024001A BR112021024001A BR112021024001A2 BR 112021024001 A2 BR112021024001 A2 BR 112021024001A2 BR 112021024001 A BR112021024001 A BR 112021024001A BR 112021024001 A BR112021024001 A BR 112021024001A BR 112021024001 A2 BR112021024001 A2 BR 112021024001A2
- Authority
- BR
- Brazil
- Prior art keywords
- lysozyme
- methods
- treatment
- broad spectrum
- infections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesma. uma formulação farmacêutica antibacteriana de amplo espectro que compreende lisozima e métodos de tratamento para prevenir ou curar doenças de etiologia bacteriana. excipientes fornecidos na formulação farmacêutica compreendendo lisozima aumentam a estabilidade e eficácia da lisozima para o tratamento de infecções bacterianas em um mamífero. a formulação farmacêutica que compreende lisozima não produz efeitos secundários prejudiciais nos tecidos ou órgãos durante o tratamento prolongado. a formulação pode ser usada para tratar infecções bacterianas da pele, regiões mucosas e administrada na corrente sanguínea de um paciente, incluindo infecções respiratórias. a formulação é útil no tratamento de infecções bacterianas, incluindo aquelas que ocorrem junto com infecções virais, particularmente infecções virais com um componente respiratório, incluindo covid-19.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962853215P | 2019-05-28 | 2019-05-28 | |
PCT/IB2020/055083 WO2020240472A1 (en) | 2019-05-28 | 2020-05-28 | Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021024001A2 true BR112021024001A2 (pt) | 2022-01-25 |
Family
ID=73551002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021024001A BR112021024001A2 (pt) | 2019-05-28 | 2020-05-28 | Formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesma |
Country Status (12)
Country | Link |
---|---|
US (3) | US20200376094A1 (pt) |
EP (1) | EP3976093A4 (pt) |
JP (1) | JP2022534776A (pt) |
CN (1) | CN114126643A (pt) |
AR (1) | AR119031A1 (pt) |
BR (1) | BR112021024001A2 (pt) |
CA (1) | CA3145530A1 (pt) |
CO (1) | CO2021017958A2 (pt) |
IL (1) | IL288531A (pt) |
MX (1) | MX2021014634A (pt) |
TW (1) | TW202110474A (pt) |
WO (1) | WO2020240472A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112805027B (zh) * | 2020-04-27 | 2023-10-10 | 广州新创忆药物临床研究有限公司 | 一种抗新冠病毒感染的药物与应用 |
WO2023133412A2 (en) * | 2022-01-05 | 2023-07-13 | Prophase Labs, Inc. | Compositions having synergistic anti-viral action and methods for treating coronavirus |
CN114503981A (zh) * | 2022-01-07 | 2022-05-17 | 上海膜益信息科技有限公司 | 一种不分层防霉液及其制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1557485A (zh) * | 2004-01-30 | 2004-12-29 | 大连帝恩生物工程有限公司 | 基因重组人溶菌酶在消除病原微生物感染炎症上的应用 |
WO2005097094A1 (en) * | 2004-04-08 | 2005-10-20 | Dermcare-Vet Pty Ltd | Antimicrobial compositions and methods for their use |
US20080095754A1 (en) * | 2006-10-18 | 2008-04-24 | Burke Susan E | Ophthalmic compositions comprising diglycine |
WO2010036938A2 (en) * | 2008-09-26 | 2010-04-01 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
UA48016U (ru) * | 2010-01-25 | 2010-02-25 | Илона Васильевна Ковач | Способ профилактики кариеса зубов у детей 3-6 лет |
UA68612U (ru) * | 2012-02-07 | 2012-03-26 | Дмитрий Викторович Дудар | Способ лечения хронического рецидивирующего афтозного стоматита у больных целиакией |
KR20190123267A (ko) * | 2017-02-28 | 2019-10-31 | 앨러멘터리 헬스 리미티드 | 호흡기 바이러스 감염에 대한 면역 반응을 유익하게 조절할 수 있는 비피도박테리움 롱검 |
US20200215169A1 (en) * | 2017-07-17 | 2020-07-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Antibacterial methods and related kits |
CN107899006A (zh) * | 2017-11-28 | 2018-04-13 | 四川清舒乐科技有限公司 | 冲洗鼻腔的药物组合物及其制备方法 |
-
2020
- 2020-05-28 TW TW109117916A patent/TW202110474A/zh unknown
- 2020-05-28 JP JP2021571513A patent/JP2022534776A/ja active Pending
- 2020-05-28 BR BR112021024001A patent/BR112021024001A2/pt unknown
- 2020-05-28 EP EP20815355.1A patent/EP3976093A4/en active Pending
- 2020-05-28 AR ARP200101510A patent/AR119031A1/es unknown
- 2020-05-28 WO PCT/IB2020/055083 patent/WO2020240472A1/en unknown
- 2020-05-28 US US16/885,537 patent/US20200376094A1/en not_active Abandoned
- 2020-05-28 MX MX2021014634A patent/MX2021014634A/es unknown
- 2020-05-28 CA CA3145530A patent/CA3145530A1/en active Pending
- 2020-05-28 CN CN202080048142.9A patent/CN114126643A/zh active Pending
-
2021
- 2021-11-29 IL IL288531A patent/IL288531A/en unknown
- 2021-12-28 CO CONC2021/0017958A patent/CO2021017958A2/es unknown
-
2022
- 2022-07-28 US US17/875,872 patent/US20220362354A1/en not_active Abandoned
-
2023
- 2023-11-09 US US18/505,472 patent/US20240066105A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3976093A1 (en) | 2022-04-06 |
TW202110474A (zh) | 2021-03-16 |
MX2021014634A (es) | 2022-07-04 |
US20200376094A1 (en) | 2020-12-03 |
AR119031A1 (es) | 2021-11-17 |
US20220362354A1 (en) | 2022-11-17 |
WO2020240472A1 (en) | 2020-12-03 |
JP2022534776A (ja) | 2022-08-03 |
IL288531A (en) | 2022-01-01 |
EP3976093A4 (en) | 2023-07-05 |
CN114126643A (zh) | 2022-03-01 |
CA3145530A1 (en) | 2020-12-03 |
US20240066105A1 (en) | 2024-02-29 |
CO2021017958A2 (es) | 2022-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021024001A2 (pt) | Formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesma | |
ES2828711T3 (es) | Formulaciones de peróxido y métodos y aplicadores para usar las mismas | |
JP2020527134A5 (pt) | ||
CN108853312B (zh) | 聚桂醇外用凝胶及其制备方法 | |
AR052047A1 (es) | Metodos de uso y composiciones comprendiendo moduladores de pde4 para el tratamiento prevencion y control de inflamacion de las vias respiratorias | |
BRPI0512311A (pt) | uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas | |
BRPI0513168A (pt) | memantina como tratamento adjunto para antipsicóticos atìpicos em pacientes com esquizofrenia | |
BR112012020185A2 (pt) | uso de preparações de heparina oral para tratar doenças e afecções do trato urinário. | |
BR112022016360A2 (pt) | Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos | |
BR112021018815A2 (pt) | Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário | |
EA201992759A1 (ru) | Ассоциация, включающая кислород и гиалуроновую кислоту, для местного вагинального применения | |
EA201170405A1 (ru) | Монотерпены для лечения заболеваний дыхательных путей, в частности, бронхолегочных заболеваний | |
BR112023000308A2 (pt) | Uso de taurolidina contra vírus | |
BR0314617A (pt) | Método para cardioproteção e neuroproteção por administração intravenosa de anestésico voláteis halogenados | |
BRPI0920492A2 (pt) | uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro. | |
Wang et al. | Tissue injury by hot fluid containing nitrogen mustard | |
ES2312421T3 (es) | Composicion farmaceutica en gel. | |
BR112018072164A2 (pt) | composição farmacêutica, método para tratamento e/ou prevenção de uma doença de pele de um paciente e/ou para alívio dos sintomas da mesma, e, uso cosmético de uma composição | |
BR112021024744A2 (pt) | Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington | |
Pardo et al. | Analgesic efficacy of topical sevoflurane on wounds | |
BR9916963A (pt) | Bupropiona para tratamento de doenças virais | |
BR112018072183A2 (pt) | composição farmacêutica, e, método para prevenir uma doença de pele | |
JP2022129327A (ja) | キカンシゼンソクの特効薬 | |
Ryabova et al. | Nasal synechia: causes and laser surgery | |
TR201619953A2 (tr) | Topi̇kal terapöti̇k formülasyonlar |